Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment?
A Lalvani - Clinical infectious diseases, 2004 - academic.oup.com
A Lalvani
Clinical infectious diseases, 2004•academic.oup.comAL is a named inventor on patents relating to T cell–based diagnosis filed by the University
of Oxford. Regulatory approval and commercialization of ELISPOT is being undertaken by a
spin-out company of the University of Oxford (Oxford Immunotec Ltd.), in which AL has a
share of equity and to which he acts as a scientific advisor.
of Oxford. Regulatory approval and commercialization of ELISPOT is being undertaken by a
spin-out company of the University of Oxford (Oxford Immunotec Ltd.), in which AL has a
share of equity and to which he acts as a scientific advisor.
AL is a named inventor on patents relating to T cell–based diagnosis filed by the University of Oxford. Regulatory approval and commercialization of ELISPOT is being undertaken by a spin-out company of the University of Oxford (Oxford Immunotec Ltd.), in which AL has a share of equity and to which he acts as a scientific advisor.
Oxford University Press